Молграмостим

Granulocyte and macrophage colony stimulating factor (GM-CSF) obtained by recombinant technology. Practically identical to the natural product found in breast milk. Indicated in neutropenia secondary to antineoplastic therapy and in bone marrow autotransplantation.

At the date of last update we found no published data on its excretion in breast milk.

Its high molecular weight makes it unlikely to be excreted in milk in significant quantities.

Its low oral bioavailability makes it difficult for it to pass into infant plasma from ingested breast milk since, due to its protein nature, it is degraded in the gastrointestinal tract and is not absorbed. ^{(Calhoun 2003)}

Other substances similar in composition and action such as Filgrastim and Lenograstim are excreted in milk in negligible amounts and have been used to treat sepsis and necrotizing enterocolitis in newborns and premature infants. ^{(Canpolat 2006, Carr 2003, Bedford 2001, Gillan 1994)}

It is a drug with very few bibliographic references and marketed in few countries.

Until more data on this drug in relation to breastfeeding are known, safer alternatives may be preferable, especially during the neonatal period and in case of prematurity.

See below the information of these related products:

• Bone Marrow Donation (Safe product and/or breastfeeding is the best option.)
• Maternal Cancer; Maternal Neoplasia (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)